Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue’s HiMice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
Menu
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue’s HiMice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

Appendix 4C – Quarterly Report and Business Update

July 31, 2017

Appendix 4C – Quarterly Report and Business Update
Investor Call
 

Categories ASX Announcements, Financial Reports
Post navigation
Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment
Investor Presentation

Recent Posts

  • LSCCB Symposium – May 2023
  • CME Talk – 17th May 2023
  • International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.
  • Annals of Oncology – ESMO Abstract 233P
  • ESMO Breast Cancer 2022, Berlin, Germany

GET IN TOUCH

51 Science Park Road, #01-11/13
The Aries, Singapore Science Park II
Singapore 117586

+65 6460 0497

contact@invitrocue.com

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Twitter Facebook-f Linkedin-in Youtube

© Copyright 2023 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings